Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2012
11/22/2012US20120294946 Modulator
11/22/2012US20120294945 Drug delivery system using hyaluronic acid-peptide conjugate micelle
11/22/2012US20120294932 Prostate Carcinogenesis Predictor
11/22/2012US20120294931 Target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and manufacturing method thereof
11/22/2012US20120294930 Combination of kinase inhibitors and uses thereof
11/22/2012US20120294929 Method of diagnosing and treating cancer using b-catenin splice variants
11/22/2012US20120294928 Method of treating scars and b-catenin-mediated disorders using nefopam compounds
11/22/2012US20120294901 Novel cochleate formulations
11/22/2012US20120294897 Bioactive fraction of petiveria alliacea, pharmaceutical composition containing same, and combination with immunostimulants for treating cancer
11/22/2012US20120294895 Protein a compositions and methods of use
11/22/2012US20120294877 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
11/22/2012US20120294875 Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
11/22/2012US20120294874 Method for Producing T Cell Receptor-Like Monoclonal Antibodies and Uses Thereof
11/22/2012US20120294873 ANTI-EpCAM IMMUNOGLOBULINS
11/22/2012US20120294872 Method of Predicting and Reducing Risk of Metastasis of Breast Cancer to Lung
11/22/2012US20120294870 Compositions and methods for diagnosis and treatment of tumors
11/22/2012US20120294867 Method for egfr directed combination treatment of cancer
11/22/2012US20120294865 Integrin Alpha-2 Binding Agents and Use Thereof to Inhibit Cancer Cell Proliferation
11/22/2012US20120294864 Endoglin Antibodies
11/22/2012US20120294863 Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
11/22/2012US20120294860 Medicament for treating and/or preventing cancer
11/22/2012US20120294859 Cancer stem cell markers and uses thereof
11/22/2012US20120294857 Monomeric Bi-Specific Fusion Protein
11/22/2012US20120294856 Compounds inhibiting cd95 signaling for the treatment of pancreatic cancer
11/22/2012US20120294853 CD19 Binding Agents and Uses Thereof
11/22/2012US20120294852 Antagonists of il-6 to raise albumin and/or lower crp
11/22/2012US20120294851 Cancer Therapies and Pharmaceutical Compositions Used Therein
11/22/2012US20120294838 Regulation of endogenous gene expression in cells using zinc finger proteins
11/22/2012US20120294831 Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
11/22/2012US20120294830 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
11/22/2012US20120294806 Drug carrier with thermal sensitivity, manufacturing method thereof, and use thereof
11/22/2012US20120294803 Cxcr4 antagonists for imaging of cancer and inflammatory disorders
11/22/2012US20120294802 Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
11/22/2012US20120294801 Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
11/22/2012US20120294800 Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
11/22/2012US20120294799 Anti-tem1 antibodies and uses thereof
11/22/2012US20120294798 Methods of treating cancer using il-21
11/22/2012US20120294797 Anti-cgrp compositions and use thereof
11/22/2012US20120294796 Antibodies Reactive with B7-H3 and Uses Thereof
11/22/2012CA2840175A1 Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
11/22/2012CA2836676A1 Method for treating non-small cell lung cancer
11/22/2012CA2836655A1 Heparin-based compositions and methods for the inhibition of metastasis
11/22/2012CA2836568A1 Immunity induction agent
11/22/2012CA2836560A1 Macrocyclic therapeutic agents and methods of treatment
11/22/2012CA2836556A1 Immunity induction agent
11/22/2012CA2836449A1 Kinase inhibitors
11/22/2012CA2836410A1 Tyrosine kinase inhibitors
11/22/2012CA2836396A1 Method for egfr directed combination treatment of cancer
11/22/2012CA2836385A1 Method for treatment of advanced solid tumors
11/22/2012CA2836277A1 Pharmaceutical compositions and methods for treating cancer
11/22/2012CA2836203A1 Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
11/22/2012CA2836028A1 Cytotoxic t cell inducer
11/22/2012CA2835885A1 Medicaments and methods for treating cancer
11/22/2012CA2835835A1 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
11/22/2012CA2835735A1 Pharmaceutical compositions comprising neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers
11/22/2012CA2835717A1 Method for treatment of solid malignancies including advanced or metastatic solid malignancies
11/22/2012CA2834699A1 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
11/22/2012CA2834566A1 Therapeutic anti-igf1r combinations
11/22/2012CA2831403A1 Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
11/21/2012EP2524926A2 Anticancer peptide sequence
11/21/2012EP2524918A1 Imidazopyrazines derivates as kinase inhibitors
11/21/2012EP2524915A1 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
11/21/2012EP2524700A1 Mucinous glycoprotein (muc-1) vaccine
11/21/2012EP2524693A1 Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
11/21/2012EP2524232A2 Methods for predicting response of triple-negative breast cancer to therapy
11/21/2012EP2523966A1 Certain chemical entities, compositions, and methods
11/21/2012EP2523958A1 Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring
11/21/2012EP2523952A1 Thiazole and oxazole kinase inhibitors
11/21/2012EP2523938A1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7
11/21/2012EP2523692A1 Biologically active molecules for influencing virus-, bacteria-, parasite-infected cells and/or tumor cells and method for the use thereof
11/21/2012EP2523686A2 Liver targeting domain antibodies
11/21/2012EP2523682A2 Notch1 binding agents and methods of use thereof
11/21/2012EP2523560A1 Compounds and methods
11/21/2012CN202537977U Taxol injection
11/21/2012CN202537976U Hydroxycamptothecin injection
11/21/2012CN1850824B Benzene-free tetrandrine and preparing method thereof
11/21/2012CN1835975B Modified human IGF-1R antibodies
11/21/2012CN102792160A Methods and compositions for treating cancer
11/21/2012CN102791856A Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
11/21/2012CN102791739A Modulators of hepatocyte growth factor activator
11/21/2012CN102791738A Antibodies binding preferentially human CSF1R extracellular domain 4 and their use
11/21/2012CN102791737A Antibodies that specifically bind to the EPHA2 receptor
11/21/2012CN102791736A Antagonists of Dsg2 for treatment of cancer
11/21/2012CN102791735A Monoclonal antibodies to progastrin and their uses
11/21/2012CN102791715A Tricyclic compounds for use as kinase inhibitors
11/21/2012CN102791711A 1, 7-diazacarbazoles and their use in the treatment of cancer
11/21/2012CN102791708A Inhibitors of akt activity
11/21/2012CN102791705A Inverse agonists and neutral antagonists for the TSH receptor
11/21/2012CN102791704A Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
11/21/2012CN102791695A Cyclopentyl- and cycloheptylpyrazoles as FXR modulators
11/21/2012CN102791690A Di-substituted pyridine derivatives as anticancers
11/21/2012CN102791296A Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to RGD binding sites
11/21/2012CN102791294A Particles for multiple agent delivery
11/21/2012CN102791293A Liver targeting molecules
11/21/2012CN102791290A A novel vaccine that targets tumor vessels as an efficient tool in tumor therapy
11/21/2012CN102787134A Self-transporter used for homologous recombination, and mucosal immune vaccine constructed thereby
11/21/2012CN102787131A Solen grandis chymotrypsin gene SgChy and recombinant protein of solen grandis chymotrypsin gene SgChy
11/21/2012CN102787119A Products and methods for treatment and/or prevention of virus infections
11/21/2012CN102787097A Modified dendritic cell and vaccine containing the same
11/21/2012CN102786603A Method for preparing chang date antineoplastic active polysaccharides by separation and purification
1 ... 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 ... 2211